Jay R. Luly - Nov 27, 2024 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
President and CEO, Director
Signature
/s/ Matthew Kowalsky as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Nov 27, 2024
Transactions value $
$0
Form type
4
Date filed
11/27/2024, 04:59 PM
Previous filing
Feb 14, 2024
Next filing
Dec 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (right to buy) Award $0 +250K $0.00 250K Nov 27, 2024 Common Stock 250K $8.83 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

Remarks:

Exhibit 24 Power of Attorney filed herewith.